Intention to treat outcome of T1 hepatocellular carcinoma with the “wait and not ablate” approach until meeting T2 criteria for liver transplant listing
Open Access
- 19 October 2015
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Liver Transplantation
- Vol. 22 (2), 178-187
- https://doi.org/10.1002/lt.24360
Abstract
Patients with T1 hepatocellular carcinoma (HCC; 1 lesion < 2 cm) are currently not eligible for priority listing for liver transplantation (LT). A common practice is to wait without locoregional therapy (LRT) until tumor growth occurs from T1 to T2 (1 lesion 2‐5 cm or 2‐3 lesions ≤ 3 cm) to be eligible for listing with Model for End‐Stage Liver Disease exception. We aimed to evaluate the intention to treat outcome of the “wait and not ablate” approach for nonresection candidates with T1 HCC until tumor growth to T2. The study included 114 patients with T1 HCC 1.0‐1.9 cm followed by serial imaging every 3 months. Two investigators performed independent imaging reviews to confirm the diagnosis. Median increase in total tumor diameter was 0.14 cm/month. Probabilities of progression from T1 to directly beyond T2 without LT listing were 4.4% at 6 months and 9.0% at both 12 and 24 months. The 1‐ and 3‐year survival was 94.5% and 75.5%. In multivariate analysis, predictors of rapid tumor progression, defined as a >1 cm increase in total tumor diameter over 3 months, included alcoholic liver disease (odds ratio [OR], 6.52; P = 0.02) and Hispanic race (OR, 3.86; P = 0.047), whereas hepatitis B appeared to be protective (OR, 0.09; P = 0.04). By competing risks regression, predictors of exclusion from LT (with or without listing for LT under T2) were alpha‐fetoprotein (AFP) ≥ 500 ng/mL (HR, 12.69; 95% confidence interval, 2.8‐57.0; P = 0.001) and rapid tumor progression (HR, 5.68; P < 0.001). In conclusion, the “wait and not ablate” approach until tumor growth from T1 to T2 before LT listing is associated with a Liver Transpl 22:178‐187, 2016. © 2015 AASLD.Keywords
This publication has 45 references indexed in Scilit:
- Hepatocellular CarcinomaThe New England Journal of Medicine, 2011
- Liver Transplantation for Hepatocellular Carcinoma: Impact of the MELD Allocation System and Predictors of SurvivalGastroenterology, 2008
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinomaLiver Transplantation, 2004
- A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: Implications for the current organ allocation policyLiver Transplantation, 2003
- Evidence‐based medicine in the treatment of hepatocellular carcinomaJournal of Gastroenterology and Hepatology, 2002
- The new liver allocation system: Moving toward evidence-based transplantation policyLiver Transplantation, 2002
- MELD and PELD: Application of survival models to liver allocationLiver Transplantation, 2001
- A model to predict survival in patients with end-stage liver diseaseHepatology, 2001
- Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with CirrhosisThe New England Journal of Medicine, 1996